Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK SLE-2
jRCT2011230001Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: SRI(4) response at Week 52. Started May 2023; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2011230001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230001.